Revive Therapeutics Aims to Expand Bucillamine Portfolio

Revive Therapeutics Ltd., a life sciences company, plans to extend its intellectual property related to bucillamine, targeting medical countermeasures and rare diseases. The Toronto-based firm aims to construct a globally protected bucillamine franchise, focusing on intellectual property protection, international market expansion, and government collaboration.

Revive seeks additional patent protection for bucillamine and is exploring new orphan and rare disease opportunities. Currently, the compound has two U.S. FDA Orphan Drug Designations for treating cystinuria and preventing ischemia-reperfusion injury during liver transplants.

The company is also pursuing collaboration opportunities through government programs in North America and internationally to support the research, development, and stockpiling of bucillamine. This strategy is part of Revive's broader goal to create partnerships with government agencies and pharmaceutical companies, enhancing the commercial viability of its therapeutic portfolio.